Create a free research account to view current pricing and place an order.
How does FOXO4 work in research models?
FOXO4-DRI is researched as a senolytic peptide concept intended to disrupt FOXO4-p53 interactions in senescent-cell models. Human use parameters and formulation standards are not established.
What is the half-life of FOXO4?
Half-life: Not standardized.
Human PK is not standardized. This is a high-caution investigational senolytic concept rather than a routine peptide protocol.
Research dosing reference
0.5-2 mg intermittent research exposure; formal clinical dosing is not standardized.
How is FOXO4 reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | DMSO or compatible solvent system may be required; verify formulation | Variable |
Injection timing
Intermittent use only in tightly structured research contexts.
Beginner escalation
Do not escalate casually; senolytic concepts require review-driven protocols.
Side-effect mitigation
Monitor systemic tolerance, inflammatory response, fatigue, and unexpected adverse effects.
Stack compatibility
Avoid stacking with other aggressive senolytic, immune-active, or mitochondrial stressors initially.
Storage & stability
Solvent choice is formulation-specific. Protect from heat/light; avoid assuming BAC compatibility.
Protocol duration & reassessment
High-caution investigational exposure only. Use short, tightly defined courses with extended reassessment intervals; do not repeat until tolerance, objective markers, and risk/benefit are reviewed. Bioregulators / Organ Support
Frequently asked questions
What is FOXO4 and how is it studied?
FOXO4-DRI is researched as a senolytic peptide concept intended to disrupt FOXO4-p53 interactions in senescent-cell models. Human use parameters and formulation standards are not established. FOXO4 is catalogued in the Longevity / Mitochondrial group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of FOXO4?
Reference half-life for FOXO4: not standardized. Human PK is not standardized. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal. Every lot of FOXO4 is third-party tested to a 99%+ purity target, with identity confirmed by mass spectrometry and purity quantified by HPLC.
How is FOXO4 stored?
Solvent choice is formulation-specific. Protect from heat/light; avoid assuming BAC compatibility. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is FOXO4 reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is DMSO or compatible solvent system may be required; verify formulation. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is FOXO4 FDA approved?
No. The research-grade FOXO4 described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration